Moderna, Inc.
MRNA
Rang în acțiuni
#239
Moderna, Inc., a biotechnology firm, is dedicated to the discovery,... Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
Preț acțiune
$241.53
Ultima sincronizare: 2026-10-20
Capitalizare de piață
$96.43B
Schimbare (1 zi)
6.45%
Schimbare (1 an)
778.61%
Țară
US
Tranzacționează Moderna, Inc. (MRNA)
Categorie
Healthcare
Venituri pentru Moderna, Inc. (MRNA)
Venituri în Jun 2026 TTM: $2.23B
Conform celor mai recente rapoarte financiare ale Moderna, Inc., venitul actual al companiei (TTM) este $2.23B. În anul 2024, compania a avut un venit de $3.20B o scădere comparativ cu venitul din anul 2023, care a fost de $6.85B. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Moderna, Inc. din 2016 până în 2026
Venituri la sfârșitul fiecărui an
| An | Venituri | Schimbă |
|---|---|---|
| 2026 (TTM) | $2.23B | 14.61% |
| 2025 | $1.94B | -39.23% |
| 2024 | $3.20B | -53.29% |
| 2023 | $6.85B | -63.72% |
| 2022 | $18.88B | 6.42% |
| 2021 | $17.74B | 2,107.63% |
| 2020 | $803.40M | 1,234.34% |
| 2019 | $60.21M | -55.42% |
| 2018 | $135.07M | -34.38% |
| 2017 | $205.83M | 89.88% |
| 2016 | $108.40M | 0.00% |
Venituri pentru companii similare sau concurente
| Companie | Venituri | Diferență de venituri | Țara |
|---|---|---|---|
| $12.62B | 466.62% |
US
|
|
| $15.74B | 606.66% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 170.26% |
NL
|
|
| $10.11B | 353.81% |
BE
|
